European Leukemia Trial Registry
Trial: CD19 CAR-T

More Details
Title Phase-I/II-Studie mit MB-CART19.1 zur Beurteilung der Sicherheit und Machbarkeit sowie zur Dosisfindung bei Patienten mit wiederkehrenden oder therapie-unempfindlichen CD19 positiven B-Zell Erkrankungen
Scientific Title A phase I/II safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies.
Short Title CD19 CAR-T
Trialgroup NN
Type of Trial multicentric, open-label
Disease Acute lymphoblastic leukemia(ALL) Ph/BCR ABL +
Acute lymphoblastic leukemia(ALL) B-Precursor ALL
Age >= 18 years
Status Active
Start of Recruitment 15.05.2018
Leader Rössig, Prof. Dr. med., Claudia
Shortprotocol Shortprotocol
created 21.02.2019 Zenawit Krüger
changed 25.06.2019 Zenawit Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |